Stockreport
AMGEN HIGHLIGHTS NEW COPD, ASTHMA AND VASCULITIS RESEARCH AT ATS 2024 [Yahoo! Finance]
Last amgen inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations: investors.amgen.com
New TAVNEOS ® (avacopan) Data in Adults With Severe Active ANCA-Associated Vasculitis With Lung Involvement THOUSAND OAKS, Calif. May 1, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of new respiratory data at the American Thoracic Society (ATS) 2024 International Conference taking place May 12-22 in San Diego . Thirteen abstracts supporting two approved medicines and one investigational treatment will be presented. "We look forward to presenting encouraging data from our Phase 2a COURSE trial in COPD with Tezspire and our Phase 1 investigational study of asthma with AMG104/AZD8630, an inhaled anti-TSLP therapy," said Jay Bradner , M.D., executive vice president of Research and Development and chief scientific officer at Amgen. "Our efforts underscore Amgen's commitment to pioneering new treatments for respiratory diseases with currently limited treatment options." Data from the COURSE trial will be presented within the Clinical Trials Symposium. COU
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | AMGN | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
AMGN alerts
AMGN alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMGN alerts
High impacting Amgen Inc. news events
Weekly update
A roundup of the hottest topics
AMGN
NEWS
NEWS
- Bone Metastasis Treatment Market To Reach USD 38.5 Billion By 2032 | DataHorizzon Research [Yahoo! Finance][Yahoo! Finance]
- We Wouldn't Be Too Quick To Buy Amgen Inc. (NASDAQ:AMGN) Before It Goes Ex-Dividend [Yahoo! Finance][Yahoo! Finance]
- Verastem Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates [Yahoo! Finance][Yahoo! Finance]
- AMGEN TO PRESENT AT THE BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE[PR Newswire]
- Amgen Inc. (NASDAQ: AMGN) had its price target raised by analysts at Mizuho from $223.00 to $235.00. They now have a "neutral" rating on the stock.[MarketBeat]
- More
AMGN
SEC Filings
SEC Filings
- 5/10/24 - Form DEFA14A
- 5/9/24 - Form 4
- 5/9/24 - Form 4
- AMGN's page on the SEC website
- More